At 5 years of follow-up of the VISTA trial, the combination of bortezomib plus melphalan and prednisone (VMP) demonstrated a survival advantage over MP alone as up-front treatment of patients with multiple myeloma who were not transplant candidates. At a median followup of 60.1 months, the absolute difference in overall survival (OS) between the treatment arms was 13 months, according to final results presented at the 53rd Annual Meeting of the American Society of Hematology. Read More ›
The best strategy for management of low-tumor-burden follicular lymphoma (FL) following response to induction therapy is controversial. The phase 3 RESORT study compared maintenance rituximab therapy versus rituximab retreatment at disease progression, and results suggest that retreatment is the preferred approach. The study was presented at the 53rd Annual Meeting of the American Society of Hematology.
Case Study
To sign up for our newsletter or print publications, please enter your contact information below.